Tango Therapeutics, Inc. (TNGX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Boston, MA, United States. The current CEO is Malte Peters.
TNGX has IPO date of 2020-09-03, 155 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $2.94B.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
